Skip to main content

Table 2 Statistical analysis a of treatment differences in change from post-saline baseline (intent-to-treat population)

From: Combined fluticasone furoate/vilanterol reduces decline in lung function following inhaled allergen 23 h after dosing in adult asthma: a randomised, controlled trial

  Treatment difference 95% CI
wmFEV 1 (L)
FF – placebo 0.162 0.087, 0.237
FF/VI – placebo 0.145 0.069, 0.222
FF/VI – FF −0.017 −0.091, 0.057
Max. percent decrease (%)
FF – placebo 10.951 8.053, 13.848
FF/VI – placebo 11.785 8.849, 14.721
FF/VI – FF 0.834 −2.010, 3.678
Max. absolute decrease in FEV 1 (L)
FF – placebo 0.330 0.232, 0.429
FF/VI – placebo 0.331 0.231, 0.431
FF/VI – FF 0.001 −0.096, 0.097
  1. aPopulation sizes analysed: placebo, n = 45; FF, n = 49; FF/VI, n = 46. Efficacy endpoints were analysed using a mixed-effects analysis of covariance (ANCOVA) model, with fixed effects of treatment, period, subject-level baseline, period-level baseline, country, sex and age and subject fitted as a random effect.
  2. CI = confidence interval; FEV1 = forced expiratory volume in 1 s; FF = fluticasone furoate; L = litres; VI = vilanterol; wm = weighted mean.